



<b>HUMANARZNEIMITTEL - EMA</b>	<b>2</b>
<i>Allgemeines – General</i>	2
<i>Pharmakovigilanz – PRAC</i>	2
<i>Zulassung – Regulatory Affairs</i>	3
<i>Orphan Drugs und neuartige Therapierichtungen (ATMP)</i>	5
<i>Qualität – Quality</i>	6
<i>(Prä-) Klinische Forschung – Research and Development</i>	7
<i>Kinderarzneimittel – Paediatrics</i>	7
<i>Pflanzliche Arzneimittel – Herbal medicines</i>	8
<b>EUROPEAN COMMISSION</b>	<b>9</b>
<b>EDQM</b>	<b>10</b>
<b>MEDIZINPRODUKTE</b>	<b>11</b>
<b>CMDH</b>	<b>12</b>
<b>HUMANARZNEIMITTEL - DEUTSCHLAND</b>	<b>13</b>
<b>HUMANARZNEIMITTEL - ÖSTERREICH</b>	<b>15</b>
<b>HUMANARZNEIMITTEL - SCHWEIZ</b>	<b>17</b>
	
<b>FRAGEN AN DAS NETZWERK</b>	<b>18</b>
<b>VERANSTALTUNGEN / EVENTS – BEHÖRDEN UND ANDERE VERANSTALTER</b>	<b>19</b>
DEUTSCHLAND	19
ÖSTERREICH	19
SCHWEIZ	19
EUROPA	19
<u><a href="#">Urheberrechtshinweis:</a></u>	

Der MEGRA Newsletter und die darin enthaltenen Beiträge sind urheberrechtlich geschützt. Ohne die ausdrückliche Genehmigung der Urheber oder der Inhaber der Nutzungsrechte darf weder der MEGRA Newsletter noch Teile davon verbreitet, bearbeitet, öffentlich zugänglich, vorgetragen, in einem Abrufsystem gespeichert oder in ein solches eingeführt oder in einer beliebigen anderen Form (elektronisch, mechanisch, per Hyperlink, per Fotokopie, per Aufzeichnung oder auf anderem Wege) oder zu einem beliebigen anderen Zweck vervielfältigt oder übermittelt werden. Downloads und Kopien des Newsletters sind nur Mitgliedern der *Mittel Europäischen Gesellschaft für Regulatory Affairs e.V. (MEGRA)* und für den privaten, nicht kommerziellen Gebrauch gestattet. Durch das Herunterladen oder Kopieren von Inhalten werden keine Rechte bezüglich der Inhalte übertragen.

## Allgemeines – General

### **EMA celebrates 30 years of progress in science and medicines in the European Union**

**Published on:** 27 - January - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/news/ema-celebrates-30-years-progress-science-medicines-european-union>

### **History of EMA**

**Published on:** 30 - January - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/about-us/history-ema>

### **One Health approach**

**Published on:** 30 - January - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/partners-networks/one-health-approach>

### **EU Innovation Network (EU-IN)**

**Published on:** 03 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/committees/working-parties-other-groups/eu-innovation-network-eu>

## Pharmakovigilanz – PRAC

### **Information on the Member States requirement for the nomination of a pharmacovigilance (PhV) contact person at national level – Human medicines requirements (updated)**

**Published on:** 14 - January - 2025

[4.a H Survey - pharmacovigilance contact person at national level H](#)

### **List of medicines under additional monitoring**

**Published on:** 29 - January - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/medicines-under-additional-monitoring/list-medicines-under-additional-monitoring>

### **Referral: Metamizole-containing medicinal products**

**Published on:** 29 - January - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/medicines/human/referrals/metamizole-containing-medicinal-products-0>

## Humanarzneimittel - EMA

### **List of European Union reference dates (EURD) and frequency of submission of periodic safety update reports (PSURs) (updated)**

**Published on:** 05 - February - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/list-european-union-reference-dates-eurd-frequency-submission-periodic-safety-update-reports-psurs\\_en.xlsx](https://www.ema.europa.eu/en/documents/other/list-european-union-reference-dates-eurd-frequency-submission-periodic-safety-update-reports-psurs_en.xlsx)

### **EudraVigilance training and support (updated)**

**Published on:** 06 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/research-development/pharmacovigilance-research-development/eudravigilance/eudravigilance-training-support>

## Zulassung – Regulatory Affairs

### **Product Management Service (PMS) roadmap**

**Published on:** 24 - January - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/product-management-service-pms-roadmap\\_en.pdf](https://www.ema.europa.eu/en/documents/other/product-management-service-pms-roadmap_en.pdf)

### **Medicinal products for human use: Monthly figures - December 2024**

**Published on:** 24 - January - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-december-2024\\_en.pdf](https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-december-2024_en.pdf)

### **CHMP opinions on consultation procedures**

**Published on:** 24 - January - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/medical-devices/consultation-procedure-ancillary-medicinal-substances-medical-devices/chmp-opinions-consultation-procedures>

### **European Shortages Monitoring Platform fully operational for monitoring of shortages in the EU**

**Published on:** 29 - January - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/news/european-shortages-monitoring-platform-fully-operational-monitoring-shortages-eu>

### **Falsified medicines: overview (updated)**

**Published on:** 30 - January - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/falsified-medicines-overview>

## Humanarzneimittel - EMA

### **Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2025**

**Published on:** 31 - January - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2025>

### **List of centrally authorised products with safety-related changes to the product information (updated)**

**Published on:** 31 - January - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/list-centrally-authorized-products-safety-related-changes-product-information\\_en.xlsx](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/list-centrally-authorized-products-safety-related-changes-product-information_en.xlsx)

### **SPOR Status Update, Event 22 January 2024**

**Presentation and Video recording available**

**Published on:** 31 - January - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/spor-status-update-1>

### **New combination of medicines to treat parasitic worm infections**

**Published on:** 31 - January - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/news/new-combination-medicines-treat-parasitic-worm-infections>

### **Member states contact points for translations review (updated)**

**Published on:** 31 - January - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/member-states-contact-points-translations-review\\_en.pdf](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/member-states-contact-points-translations-review_en.pdf)

### **Availability of medicines before and during crises (updated)**

**Published on:** 03 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/medicine-shortages-availability-issues/availability-medicines-during-crises>

### **Nanotechnology-based medicinal products for human use EU-IN Horizon Scanning Report**

**Published on:** 03 - February - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/report/nanotechnology-based-medicinal-products-human-use-eu-horizon-scanning-report\\_en.pdf](https://www.ema.europa.eu/en/documents/report/nanotechnology-based-medicinal-products-human-use-eu-horizon-scanning-report_en.pdf)

### **CHMP: Working parties and other groups (several updated working groups)**

**Published on:** 04 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/committees/working-parties-other-groups/chmp-working-parties-other-groups>

**Questions and answers clinic on post-authorisation procedure management in IRIS, Event 08 January 2024**

**Video recording available**

**Published on:** 04 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/questions-answers-clinic-post-authorisation-procedure-management-iris>

**Questions and answers clinic on post-authorisation procedure management in IRIS, Event 17 January 2024**

**Video recording available**

**Published on:** 05 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/questions-answers-clinic-post-authorisation-procedure-management-iris-17-jan-2025>

**Medicine shortages and availability issues (updated)**

**Published on:** 06 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/medicine-shortages-availability-issues>

**Product Management Service (PMS) webinar on Product User Interface (PUI) edit functionalities for industry users, Event 28 January 2024**

**Presentation and Video recording available**

**Published on:** 06 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/product-management-service-pms-webinar-product-user-interface-pui-edit-functionalities-industry-users>

**Plasma master file certificates (updated)**

**Published on:** 06 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/plasma-master-file-pmf-certification/plasma-master-file-certificates>

### Orphan Drugs und neuartige Therapierichtungen (ATMP)

**Committee for Advanced Therapies (CAT), Event 4-6 December 2024**

**Minutes available**

**Published on:** 28 - January - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-4-6-december-2024\\_en.pdf](https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-4-6-december-2024_en.pdf)

## Humanarzneimittel - EMA

### ***Procedural advice for orphan medicinal product designation: Guidance for sponsors (updated)***

***Published on:*** 30 - January - 2025

***For more information, please refer to:***

[https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-orphan-medicinal-product-designation-guidance-sponsors\\_en.pdf](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-orphan-medicinal-product-designation-guidance-sponsors_en.pdf)

### ***COMP work plan 2025***

***Published on:*** 30 - January - 2025

***For more information, please refer to:***

[https://www.ema.europa.eu/en/documents/work-programme/comp-work-plan-2025\\_en.pdf](https://www.ema.europa.eu/en/documents/work-programme/comp-work-plan-2025_en.pdf)

### ***Committee for Advanced Therapies (CAT): Work Plan 2025***

***Published on:*** 03 - February - 2025

***For more information, please refer to:***

[https://www.ema.europa.eu/en/documents/work-programme/committee-advanced-therapies-cat-work-plan-2025\\_en.pdf](https://www.ema.europa.eu/en/documents/work-programme/committee-advanced-therapies-cat-work-plan-2025_en.pdf)

### ***Submission deadlines for orphan designations (updated)***

***Published on:*** 06 - February - 2025

***For more information, please refer to:***

<https://www.ema.europa.eu/en/human-regulatory-overview/research-development/orphan-designation-research-development/applying-orphan-designation/submission-deadlines-orphan-designations>

## Qualität – Quality

### ***ICH E6 Good clinical practice - Scientific guideline (updated)***

***Published on:*** 27 - January - 2025

***For more information, please refer to:***

<https://www.ema.europa.eu/en/ich-e6-good-clinical-practice-scientific-guideline>

### ***Guidance on good manufacturing practice and good distribution practice: Questions and answers***

***Published on:*** 31 - January - 2025

***For more information, please refer to:***

<https://www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-manufacturing-practice/guidance-good-manufacturing-practice-good-distribution-practice-questions-answers>

### ***Qualification of non-mutagenic impurities - Scientific guideline (updated)***

***Published on:*** 03 - February - 2025

***For more information, please refer to:***

<https://www.ema.europa.eu/en/qualification-non-mutagenic-impurities-scientific-guideline>

## (Prä-) Klinische Forschung – Research and Development

### **Clinical trial information system (CTIS) public portal full trial information (updated)**

**Published on:** 29 - January - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/clinical-trial-information-system-ctis-public-portal-full-trial-information\\_en.pdf](https://www.ema.europa.eu/en/documents/other/clinical-trial-information-system-ctis-public-portal-full-trial-information_en.pdf)

### **Product-specific bioequivalence guidance (updated)**

**Published on:** 31 - January - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/research-and-development/scientific-guidelines/clinical-pharmacology-pharmacokinetics/product-specific-bioequivalence-guidance>

### **Clinical Trials Regulation becomes fully applicable**

**Published on:** 31 - January - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/news/clinical-trials-regulation-becomes-fully-applicable>

### **Clinical Trials Information System (CTIS): Walk-in clinic, Event 29 January 2025**

**Video recording available**

**Published on:** 31 - January - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/clinical-trials-information-system-ctis-walk-clinic-january-2025>

### **Clinical Trials Information System (CTIS): training and support (updated)**

**Published on:** 05 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/research-development/clinical-trials-human-medicines/clinical-trials-information-system-ctis-training-support>

### **Page: Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials - Scientific guideline (updated)**

**Published on:** 06 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy-medicinal-products-clinical-trials-scientific-guideline>

## Kinderarzneimittel – Paediatrics

**No news published**



## Pflanzliche Arzneimittel – Herbal medicines

### ***HMPC: overview of assessment work - priority list (updated)***

***Published on:*** 28 - January - 2025

***For more information, please refer to:***

[https://www.ema.europa.eu/en/documents/other/hmpc-overview-assessment-work-priority-list\\_en.pdf](https://www.ema.europa.eu/en/documents/other/hmpc-overview-assessment-work-priority-list_en.pdf)

### ***Document: Committee on Herbal Medicinal Products (HMPC): Work Plan 2025***

***Published on:*** 30 - January - 2025

***For more information, please refer to:***

[https://www.ema.europa.eu/en/documents/work-programme/committee-herbal-medicinal-products-hmpc-work-plan-2025\\_en.pdf](https://www.ema.europa.eu/en/documents/work-programme/committee-herbal-medicinal-products-hmpc-work-plan-2025_en.pdf)

### ***Draft reflection paper on the use of information in European Union herbal monographs and assessment reports for borderline issues***

***Published on:*** 31 - January - 2025

***For more information, please refer to:***

[https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-use-information-european-union-herbal-monographs-assessment-reports-borderline-issues\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-use-information-european-union-herbal-monographs-assessment-reports-borderline-issues_en.pdf)



***EU Health Policy Platform: The 2024 Thematic Networks cycle has come to an end – what's next?***

***Published on:*** 29 - January - 2025

***For more information, please refer to:***

<https://ec.europa.eu/newsroom/sante/newsletter-archives/59624>

***Is the EU Health Policy Platform right for you? Find out, by taking a quick look at these two infographics***

***Published on:*** 03 - February - 2025

***For more information, please refer to:***

[https://health.ec.europa.eu/latest-updates/eu-health-policy-platform-right-you-find-out-taking-quick-look-these-two-infographics-2025-02-03\\_en](https://health.ec.europa.eu/latest-updates/eu-health-policy-platform-right-you-find-out-taking-quick-look-these-two-infographics-2025-02-03_en)

***The Commission opens first request submission period for joint scientific consultations***

***Published on:*** 03 - February - 2025

***For more information, please refer to:***

<https://ec.europa.eu/newsroom/sante/newsletter-archives/59790>

***New pandemic preparedness facilities inaugurated under HERA's EUFab network***

***Published on:*** 03 - February - 2025

***For more information, please refer to:***

[https://health.ec.europa.eu/latest-updates/new-pandemic-preparedness-facilities-inaugurated-under-heras-eufab-network-2025-02-03\\_en](https://health.ec.europa.eu/latest-updates/new-pandemic-preparedness-facilities-inaugurated-under-heras-eufab-network-2025-02-03_en)

***New HERA study maps global pandemic preparedness structures***

***Published on:*** 04 - February - 2025

***For more information, please refer to:***

[https://health.ec.europa.eu/latest-updates/new-hera-study-maps-global-pandemic-preparedness-structures-2025-02-04\\_en](https://health.ec.europa.eu/latest-updates/new-hera-study-maps-global-pandemic-preparedness-structures-2025-02-04_en)

***Coordinated assessment for clinical investigations: a call for expression of interest***

***Published on:*** 06 - February - 2025

***For more information, please refer to:***

[https://health.ec.europa.eu/medical-devices-clinical-investigations-and-performance-studies/pilot-coordinated-assessment-cips\\_en](https://health.ec.europa.eu/medical-devices-clinical-investigations-and-performance-studies/pilot-coordinated-assessment-cips_en)

***EDQM reference standards monthly newsletter – January 2025***

***Published on: 03 - February - 2025***

***For more information, please refer to:***

***<https://www.edqm.eu/en/-/edqm-reference-standards-monthly-newsletter-january-2025>***

## Medizinprodukte

**Revised versions and new guidance are available in the EMDN section**

**Published on:** 28 - January - 2025

**For more information, please refer to:**

[https://health.ec.europa.eu/medical-devices-sector/new-regulations/guidance-mdcq-endorsed-documents-and-other-guidance\\_en](https://health.ec.europa.eu/medical-devices-sector/new-regulations/guidance-mdcq-endorsed-documents-and-other-guidance_en)

**Questions and answers on implementation of the medical devices and in vitro diagnostic medical devices Regulations ((EU) 2017/745 and (EU) 2017/746)**

**Published on:** 05 - February - 2025

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-answers-implementation-medical-devices-vitro-diagnostic-medical-devices-regulations-eu-2017-745-eu-2017-746\\_en.pdf](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-answers-implementation-medical-devices-vitro-diagnostic-medical-devices-regulations-eu-2017-745-eu-2017-746_en.pdf)

or

[https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-answers-implementation-medical-devices-vitro-diagnostic-medical-devices-regulations-eu-2017-745-eu-2017-746-tracked-changes\\_en.pdf](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-answers-implementation-medical-devices-vitro-diagnostic-medical-devices-regulations-eu-2017-745-eu-2017-746-tracked-changes_en.pdf) (track change version)

**CMDH PRESS RELEASES 2025**

**Published on:** 05 - February - 2025

**For more information, please refer to:**

<https://www.hma.eu/human-medicines/cmdh/press-releases.html#c7615>

**Request for RMS in a Decentralised Procedure, medicinal products for human use**

**Published on:** 06 - February - 2025

**For more information, please refer to:**

<https://www.hma.eu/human-medicines/cmdh/templates/applications-for-ma.html#c1665>

**Procedural Advice on Repeat Use**

**Published on:** 06 - February - 2025

**For more information, please refer to:**

<https://www.hma.eu/human-medicines/cmdh/procedural-guidance/application-for-ma/mrp/rup.html#c1636>

**CMDh SOP on decision-making process for new active substance status or extension of marketing protection or data exclusivity**

**Published on:** 06 - February - 2025

**For more information, please refer to:**

<https://www.hma.eu/human-medicines/cmdh/procedural-guidance/application-for-ma.html#c4986>

**Best Practice Guides (BPGs) for the Submission and Processing of Variations in the Mutual Recognition Procedure**

**Published on:** 06 - February - 2025

**For more information, please refer to:**

<https://www.hma.eu/human-medicines/cmdh/procedural-guidance/variation.html#c2126>

**Best Practice Guide on (1) Introduction of substances/combinations onto the EURD list and setting the initial PSUR DLP and frequency and (2) Assessment of PSURs of products where the EU Reference Date is not yet legally binding/followed**

**Published on:** 06 - February - 2025

**For more information, please refer to:**

<https://www.hma.eu/human-medicines/cmdh/pharmacovigilance/psur/bpg-on-1-introduction-of-substances/combinations-onto-the-eurd-list-and-setting-the-initial-psur-dlp-and-frequency-and-2-assessment-of-psurs-of-products-where-the-eu-reference-date-is-not-yet-legally-binding.html#c7149>

# Humanarzneimittel - Deutschland

## **Arzneibuchkommissionen**

**Veröffentlicht am:** 27 - Januar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Arzneimittel/Zulassung/Zulassungsrelevante-Themen/Arzneibuch/Arzneibuchkommissionen/artikel.html?nn=986770>

## **BfArM erweitert öffentlichen Zugang zu Arzneimittel- und Zulassungsdaten**

**Veröffentlicht am:** 29 - Januar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/SharedDocs/Pressemitteilungen/DE/2025/pm01-2025.html?nn=986770>

## **Derzeit gültige Monografien der Standardzulassung für Humanarzneimittel (Stand 29.01.2025)**

**Veröffentlicht am:** 29 - Januar - 2025

**Weitere Informationen finden Sie unter:**

[https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Zulassung/ZulRelThemen/stdZulundReq/aktuell\\_queltige\\_liste\\_standardzulassungen.html?nn=986770](https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Zulassung/ZulRelThemen/stdZulundReq/aktuell_queltige_liste_standardzulassungen.html?nn=986770)

## **Maßnahmen des BfArM und ergänzende Informationen zu Lieferengpässen**

**Veröffentlicht am:** 30 - Januar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Lieferengpaesse/Massnahmen-des-BfArM/artikel.html?nn=986770>

## **Statistik "Besondere Therapierichtungen und Traditionelle Arzneimittel"**

**Veröffentlicht am:** 03 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Aktuelles/Statistiken/Arzneimittelzulassung/Besondere-Therapierichtungen/artikel.html?nn=986770>

## **Arzneimittelinformationssystem AMIce**

**Veröffentlicht am:** 03 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Arzneimittel-recherchieren/AMIce/artikel.html?nn=986770>

## **Aktuell laufende und bestätigte Arzneimittel-Härtefallprogramme**

**Veröffentlicht am:** 03 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Arzneimittel/Klinische-Pruefung/Compassionate-Use/compUse-tabelle.html?nn=986770>

## **Umsetzung des Durchführungsbeschlusses der Europäischen Kommission zum PSUR Single Assessment betreffend die Zulassungen für Humanarzneimittel mit dem Wirkstoff Pemetrexed vom 23.01.2025**

**Veröffentlicht am:** 03 - Februar - 2025

**Weitere Informationen finden Sie unter:**

[https://www.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/Periodic-Safety-Update-Reports\\_PSURs/PSUR-Single-Assessment/Anlagen/m-r/Pemetrexed2-durchfuehrungsbeschluss-EU.html?nn=986770](https://www.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/Periodic-Safety-Update-Reports_PSURs/PSUR-Single-Assessment/Anlagen/m-r/Pemetrexed2-durchfuehrungsbeschluss-EU.html?nn=986770)

## Humanarzneimittel - Deutschland

### **Arzneimittel-Lieferengpass-bekämpfungsgesetz (ALBVVG)**

**Veröffentlicht am:** 04 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Lieferengpaesse/ALBVVG/artikel.html?nn=986770>

### **Förderung der Nutzung von SNOMED CT durch die EU Kommission**

**Veröffentlicht am:** 06 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Kodiersysteme/Terminologien/SNOMED-CT/eu-foerderung/artikel.html?nn=986770>

### **Informationen zu Einreichung und Genehmigung von Schulungsmaterial**

**Veröffentlicht am:** 06 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/Risikoinformationen/Schulungsmaterial/Zusatzinformationen/artikel.html?nn=986770>

### **Clinical Trials Information System – CTIS**

**Veröffentlicht am:** 06 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Arzneimittel/Klinische-Pruefung/CTIS-Clinical-Trials-Information-System/artikel.html?nn=986770>

# Humanarzneimittel - Österreich

## **BASG "All-in-One Register"**

**Veröffentlicht am:** 24 - Januar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.basq.gv.at/marktbeobachtung/oeffentliche-register/basq-all-in-one-register>

## **Arzneispezialitäten Übersicht 2024**

**Veröffentlicht am:** 29 - Januar - 2025

**Weitere Informationen finden Sie unter:**

[https://www.basq.gv.at/fileadmin/redakteure/02\\_Ueber\\_Uns/Statistik/Arzneispezialit%C3%A4ten\\_%C3%9Cbersicht\\_2024.pdf](https://www.basq.gv.at/fileadmin/redakteure/02_Ueber_Uns/Statistik/Arzneispezialit%C3%A4ten_%C3%9Cbersicht_2024.pdf)

## **Zulassungen Registrierungen Zusatzdaten 2024**

**Veröffentlicht am:** 29 - Januar - 2025

**Weitere Informationen finden Sie unter:**

[https://www.basq.gv.at/fileadmin/redakteure/02\\_Ueber\\_Uns/Statistik/Zulassungen\\_Registrierungen\\_Zusatzdaten\\_2024.pdf](https://www.basq.gv.at/fileadmin/redakteure/02_Ueber_Uns/Statistik/Zulassungen_Registrierungen_Zusatzdaten_2024.pdf)

## **Registrierung in IRIS**

**Veröffentlicht am:** 29 - Januar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.basq.gv.at/fuer-unternehmen/zulassung-life-cycle/zulassungsverfahren/registrierung-in-iris>

## **Pharmakovigilanz-Inspektion**

**Veröffentlicht am:** 30 - Januar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.basq.gv.at/fuer-unternehmen/pharmakovigilanz/pharmakovigilanz-inspektion>

## **RMS NEWS**

**Veröffentlicht am:** 31 - Januar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.basq.gv.at/fuer-unternehmen/zulassung-life-cycle/oesterreich-als-rms/rms-news>

## **PSUR outcome: Metformin**

**Veröffentlicht am:** 04 - Februar - 2025

**Weitere Informationen finden Sie unter:**

[Mustertext Metformin](#)

[Link zur Webseite der EMA](#)

## **PSUR outcome: Fentanyl (transdermales Pflaster, Injektionslösung)**

**Veröffentlicht am:** 04 - Februar - 2025

**Weitere Informationen finden Sie unter:**

[Mustertext Metformin](#)

[Link zur Webseite der EMA](#)



# Humanarzneimittel - Österreich

**PSUR outcome: Pemetrexed**

**Veröffentlicht am:** 07 - Januar - 2025

**Weitere Informationen finden Sie unter:**

[Mustertext Pemetrexed](#)

[Link zur Webseite der EC](#)

**PSUR outcome: Ambrosia artemisifolia (sublinguale Anwendung)**

**Veröffentlicht am:** 04 - Februar - 2025

**Weitere Informationen finden Sie unter:**

[Mustertext Ambrosia artemisifolia \(sublinguale Anwendung\)](#)

[Link zur Webseite der EMA](#)

**PSUR outcome: Promethazin**

**Veröffentlicht am:** 04 - Februar - 2025

**Weitere Informationen finden Sie unter:**

[Link zur Webseite der EMA](#)

**PSUR outcome: Nebivolol**

**Veröffentlicht am:** 04 - Februar - 2025

**Weitere Informationen finden Sie unter:**

[Mustertext Nebivolol](#)

[Link zur Webseite der EMA](#)

**PSUR outcome: Oxaliplatin**

**Veröffentlicht am:** 06 - Februar - 2025

**Weitere Informationen finden Sie unter:**

[Mustertext Oxaliplatin](#)

[Link zur Webseite der EMA](#)

**Beratung durch das BASG**

**Veröffentlicht am:** 05 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.basg.gv.at/ueber-uns/basg-veroeffentlichungen/geschaeftsordnung>

**Statistiken**

**Veröffentlicht am:** 06 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.basg.gv.at/ueber-uns/statistiken>

## Humanarzneimittel - Schweiz

### **Vermeintlich pflanzliche Produkte**

**Veröffentlicht am:** 28 - Januar - 2025

**Weitere Informationen finden Sie unter:**

[https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/marktueberwachung/arzneimittel-aus-dem-internet/drug-safety-current-threats/warnung\\_pflanzlichen\\_produkten.html](https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/marktueberwachung/arzneimittel-aus-dem-internet/drug-safety-current-threats/warnung_pflanzlichen_produkten.html)

### **Neue Schweizerische Gute Praxis für die Instandhaltung von Medizinprodukten**

**Veröffentlicht am:** 31 - Januar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.swissmedic.ch/swissmedic/de/home/medizinprodukte/wiederaufbereitung---instandhaltung/instandhaltung.html>

### **Revidierte Auslegung des Mutual Recognition Agreement (MRA) zwischen der Schweiz und Kanada**

**Veröffentlicht am:** 31 - Januar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.swissmedic.ch/swissmedic/de/home/news/mitteilungen/abkommen-ca-und-ch.html>

### **Swissmedic Journal**

**Veröffentlicht am:** 07 - Februar - 2025

**Weitere Informationen finden Sie unter:**

<https://www.swissmedic.ch/swissmedic/de/home/ueber-uns/publikationen/swissmedic-journal.html>

### **Aktualisierte Vorgabedokumente**

**Veröffentlicht am:** 06 - Februar - 2025

**Weitere Informationen finden Sie unter:**

[https://www.swissmedic.ch/swissmedic/de/home/news/updates/updated\\_documents.html](https://www.swissmedic.ch/swissmedic/de/home/news/updates/updated_documents.html)



## Fragen an das Netzwerk

**Falls Sie eine Frage haben, die Sie gerne in unserem Netzwerk diskutieren würden, senden Sie uns einfach eine E-Mail an [info-as@megra.org](mailto:info-as@megra.org) zur anonymen Publikation im nächsten Newsletter.\***

\*Bei der Beantwortung der Fragen handelt es sich um eine Zusammenfassung von persönlichen Meinungen und Erfahrungswerten der MEGRA Mitglieder mit keinem Anspruch auf Rechtssicherheit. Wir empfehlen zur Absicherung die Konsultation entsprechender zugrunde liegender Regularien.

# Veranstaltungen / Events – Behörden und andere Veranstalter

## Deutschland

### **Gemeinsame Ringvorlesung Wintersemester 2024/2025**

**Ort:** online

**Termin:** verschiedene 2024 - 2025

**Weitere Informationen finden Sie unter:**

[https://www.bfarm.de/DE/Aktuelles/Veranstaltungen/Ringvorlesung/Termine/Ringvorlesung\\_2024-2025.html?nn=986770](https://www.bfarm.de/DE/Aktuelles/Veranstaltungen/Ringvorlesung/Termine/Ringvorlesung_2024-2025.html?nn=986770)

### **Workshop der Arbeitsgruppe Chemometrics and Quality Assurance zur Datenvisualisierung**

**Ort:** Paul-Ehrlich-Institut, Langen

**Termin:** 02 bis 03 - April - 2025

**Weitere Informationen finden Sie unter:**

<https://www.pei.de/SharedDocs/veranstaltungen-events/DE/2025/2025-04-02-qdch-workshop.html?nn=170994>

## Österreich

**Keine Veranstaltungen veröffentlicht**

## Schweiz

**Keine Veranstaltungen veröffentlicht**

## Europa

### **eXtended EudraVigilance Medicinal Product Dictionary (XEVMPPD) training course - February 2025**

**Where:** online

**Date:** 10 to 12 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/extended-eudravigilance-medicinal-product-dictionary-xevmpd-training-course-february-2025>

### **ACT EU workshop on ICH E6 R3 (principles and Annex 1)**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 19 to 20 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/act-eu-workshop-ich-e6-r3-principles-annex-1>

## Veranstaltungen / Events – Behörden und andere Veranstalter

### **Virtual live hands-on training course for clinical trials sponsors using EudraVigilance system**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 18 to 20 - February - 2025, 05 to 07 - May - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/virtual-live-hands-training-course-clinical-trials-sponsors-using-eudravigilance-system-february>

<https://www.ema.europa.eu/en/events/virtual-live-hands-training-course-clinical-trials-sponsors-using-eudravigilance-system-may>

### **European Shortages Monitoring Platform (ESMP) training on crisis and MSSG-led preparedness reporting for marketing authorisation holders (MAHs)**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 19 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/european-shortages-monitoring-platform-esmp-training-crisis-mssg-led-preparedness-reporting-marketing-authorisation-holders-mahs>

### **European Shortages Monitoring (ESMP) - Question and answer clinic for marketing authorisation holders on shortage reporting via ESMP**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 25 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/european-shortages-monitoring-esmp-question-answer-clinic-marketing-authorisation-holders-shortage-reporting-esmp>

### **Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API)**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 04, 11, 18, 25 - February - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/qa-clinic-product-management-service-pms-product-user-interface-pui-application-programming-interface-api-4-february-2025>

<https://www.ema.europa.eu/en/events/qa-clinic-product-management-service-pms-product-user-interface-pui-application-programming-interface-api-11-february-2025>

<https://www.ema.europa.eu/en/events/qa-clinic-product-management-service-pms-product-user-interface-pui-application-programming-interface-api-18-february-2025>

<https://www.ema.europa.eu/en/events/qa-clinic-product-management-service-pms-product-user-interface-pui-application-programming-interface-api-25-february-2025>

## Veranstaltungen / Events – Behörden und andere Veranstalter

### ***Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system***

***Where:*** online

***Date:*** 24 to 28 - February - 2025

***For more information, please refer to:***

<https://www.ema.europa.eu/en/events/mandatory-use-iso-ich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-47>

### ***Training on human variations web-based electronic application form (eAF) functionalities for CAPs and non-CAPs variations***

***Where:*** online and European Medicines Agency, Amsterdam, the Netherlands

***Date:*** 27 - February - 2025

***For more information, please refer to:***

<https://www.ema.europa.eu/en/events/training-human-variations-web-based-electronic-application-form-eaf-functionalities-caps-non-caps-variations>

### ***EMA workshop on the challenges in drug development, regulation and clinical practice for immunoglobulins***

***Where:*** online and European Medicines Agency, Amsterdam, the Netherlands

***Date:*** 05 - March - 2025

***For more information, please refer to:***

<https://www.ema.europa.eu/en/events/ema-workshop-challenges-drug-development-regulation-clinical-practice-immunoglobulins>

### ***Clinical Trials Information System (CTIS) bitesize talk: Change of sponsor in CTIS***

***Where:*** online and European Medicines Agency, Amsterdam, the Netherlands

***Date:*** 05 - March - 2025

***For more information, please refer to:***

<https://www.ema.europa.eu/en/events/clinical-trials-information-system-ctis-bitesize-talk-change-sponsor-ctis>

### ***Webinar on reflection paper on the qualification of non-mutagenic impurities***

***Where:*** online and European Medicines Agency, Amsterdam, the Netherlands

***Date:*** 06 - March - 2025

***For more information, please refer to:***

<https://www.ema.europa.eu/en/events/webinar-reflection-paper-qualification-non-mutagenic-impurities>

## Veranstaltungen / Events – Behörden und andere Veranstalter

### **Q&A clinic on web-based electronic Application Form (eAF) functionalities for CAPs and non-CAPs variations**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 06 & 13 - March - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/qa-clinic-web-based-electronic-application-form-eaf-functionalities-caps-non-caps-variations-0>

<https://www.ema.europa.eu/en/events/qa-clinic-web-based-electronic-application-form-eaf-functionalities-caps-non-caps-variations>

### **DIA Europe 2025**

**Where:** Congress Centre Basel, Switzerland

**Date:** 18 to 20 - March - 2025

**For more information, please refer to:**

<https://www.edqm.eu/en/w/dia-europe-2025>

### **Clinical Trials Information System (CTIS) sponsor end user training programme - March 2025**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 25 to 28 - March - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/clinical-trials-information-system-ctis-sponsor-end-user-training-programme-march-2025>

### **EDQM Stakeholder Event on “Plasma Supply Continuity”**

**Where:** Congress Centre Basel, Switzerland

**Date:** 26 to 27 - March - 2025

**For more information, please refer to:**

<https://www.edqm.eu/en/plasma-supply-continuity>

### **SPOR and XEVMPD status update webinar**

**Where:** Live broadcast

**Date:** 09 - April - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/spor-xevmpd-status-update-webinar>

### **Product Management Service (PMS) information day 2025**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 21 - May - 2025

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/product-management-service-pms-information-day-2025>